A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
Part of paid clinical trials in Cherry Hill, New Jersey.
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study ID
- NCT07767903
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Generalized Anxiety Disorder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SEP-363856 — DRUGOral tablet
- Placebo — DRUGOral tablet
Study Details
This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).
Key Dates
- First listed
- Aug 17, 2026
- Start date
- Aug 7, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 25, 2028
- Completion
- Nov 1, 2028
Study Design
- Enrollment
- 384 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SEP-363856Participants will receive SEP-363856, 50 mg (Days 1 to 3) and 75 mg/day tablet, from Days 4 to 56, orally, QD.
- Placebo Comparator: PlaceboParticipants will receive SEP-363856-matching placebo tablet, orally, QD from Days 1 to 56.
Primary Outcome Measure
Change From Baseline at Week 8 in Hamilton Anxiety Rating Scale (HAM-A) Total Score [ Time Frame: Baseline, Week 8 ]
Central Contacts
- Otsuka Call Center844-687-8522
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Lumina Clinical Research Center | Cherry Hill | New Jersey | 08002 | Corcoran (PRINCIPAL_INVESTIGATOR) |
| Basil Clinical | Jamaica | New York | 11413 | Rapp (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Cherry Hill, NJ
Related Studies
- Triage Survey for Psychiatry Research EligibilityRecruiting · Adams Clinical · Boston, Massachusetts
- Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety DisorderPHASE2 · Recruiting · Intra-Cellular Therapies, Inc. · Glendale, California
- Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderPHASE2 · Recruiting · Intra-Cellular Therapies, Inc. · Birmingham, Alabama
- RE104 Safety and Efficacy Study in Generalized Anxiety DisorderPHASE2 · Recruiting · Reunion Neuroscience Inc · Gilbert, Arizona